Quoin Pharmaceuticals (QNRX) investor relations material

Executive summary

• Transitioned from clinical stage to preparing for commercial readiness, driven by regulatory and clinical milestones.

• Secured significant financing and advanced QRX003 for Netherton Syndrome with regulatory designations in the U.S., Europe, Japan, and Saudi Arabia.

• Expanded clinical studies for QRX003 and proprietary rapamycin platforms, targeting multiple rare diseases.

• Launched a global awareness campaign achieving over 2 million video views and 24 million impressions.

Financial highlights

• Closed private placement financing raising up to $104.5 million, with $16.5 million at closing and up to $88 million from warrant exercises.

• Cash, cash equivalents, and marketable securities totaled $18.7 million as of December 31, 2025.

• Net loss for Q4 2025 was $4.3 million, up from $2.3 million in Q4 2024; full-year net loss was $15.8 million, up from $9.0 million in 2024.

• Operating expenses for 2025 were $16.3 million, up from $9.5 million in 2024.

Outlook and guidance

• Year-end cash position expected to fund operations into 2027.

• Plans to initiate Phase 3 study for QRX003 in 2026, with potential NDA filing in 2027.

• Anticipates reporting topline data from two whole-body clinical trials for Netherton Syndrome in 2H 2026.

• Proof-of-concept clinical testing for rapamycin platforms planned for 2H 2026.